Држава: Канада
Језик: Енглески
Извор: Health Canada
DESOGESTREL; ETHINYL ESTRADIOL; DESOGESTREL; ETHINYL ESTRADIOL; DESOGESTREL; ETHINYL ESTRADIOL
ASPEN PHARMACARE CANADA INC.
G03AB05
DESOGESTREL AND ESTROGEN
0.1MG; 0.025MG; 0.125MG; 0.025MG; 0.15MG; 0.025MG
TABLET
DESOGESTREL 0.1MG; ETHINYL ESTRADIOL 0.025MG; DESOGESTREL 0.125MG; ETHINYL ESTRADIOL 0.025MG; DESOGESTREL 0.15MG; ETHINYL ESTRADIOL 0.025MG
ORAL
21
Prescription
CONTRACEPTIVES
Active ingredient group (AIG) number: 0650285001; AHFS:
APPROVED
2018-02-01
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LINESSA ® 21 AND PR LINESSA ® 28 desogestrel and ethinyl estradiol tablets USP 0.100 mg, 0.025 mg 0.125 mg, 0.025 mg 0.150 mg, 0.025 mg Oral Contraceptive G03AB05 Aspen Pharmacare Canada Inc. 8 – 1155 North Service Road West Oakville, ON L6M 3E3 Date of Initial Approval: June 13, 2006 Date of Preparation: September 12, 2023 Trademarks are owned by or licensed to the Aspen Group of companies. © 2023 Aspen Group of companies or its licensor. All rights reserved. Submission Control No: 273119 _ _ LINESSA ® 21 and LINESSA ® 28 (desogestrel and ethinyl estradiol tablets) © 2023 Aspen Group of companies or its licensor. All rights reserved. _ _ _Page 2 of 72_ RECENT MAJOR LABEL CHANGES Contraindications (2) 09/2023 Warnings and Precautions (7) 09/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 6 4.1 Dosing Considerations ........................................................................................ Прочитајте комплетан документ